For more than 135 years, we have been united by a singular purpose: to find cures for sarcomas. 1-844-923-0361 (new pts) | [email protected] (doctors)
New York, NY
Joined July 2020
- Tweets114
- Following292
- Followers702
- Likes255
Sarcoma Service at Memorial Sloan Kettering retweeted
The July episode of #SARCTalk features Dr. Mark Dickson, MD from @MSKCancerCenter sharing valuable insight on #liposarcoma.
Listen now on Spotify! Also available on Apple Podcast and YouTube. open.spotify.com/episode/5Wf…
#sarcoma #SARCtrials @MSKSarcoma
Featured today by @MSKLibrary: A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma dx.doi.org/10.1158/1078-0432…
Sarcoma Service at Memorial Sloan Kettering retweeted
"This grant is meaningful to me because it allows me to continue my research which is focused on novel immunotherapies for rare pediatric cancers," shares CRI-Bristol Myers Squibb Fellow Dr. Lauren Banks of @MSKCancerCenter. Learn more: bit.ly/3LFpFwv #CancerResearch
Sarcoma Service at Memorial Sloan Kettering retweeted
On 4/26, we're launching a global educational series on molecular oncology, co-directed by MSK's Dr. Mrinal Gounder and @SewantiLimaye of @RFhospital Mumbai, to examine cancer signaling pathways and discuss nuances of precision therapies. Register today! bit.ly/3oDMGpS?utm_campaign=…
Sarcoma Service at Memorial Sloan Kettering retweeted
Dr. Kelly shows that pembrolizumab + epacadostat is ineffective in #sarcoma but correlative studies noted lack of IDO inhibition. Provides some important insight into potential mechanism of drug failure, leaving many unanswered questions. @MSKSarcoma @MSK_DeptOfMed
Out today @CCR_AACR from Dr. Ciara M. Kelly, @sandrapdangelo @MSKCancerCenter
A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma aacrjournals.org/clincancerr…
We are thrilled to welcome Dr. Bob Maki back to the MSK family. Dr. Maki brings long-standing expertise in #sarcoma through innovative research and trials. A dedicated colleague, mentor, friend and a compassionate clinician. Clinics in Manhattan and Nassau campus. Welcome Bob!
Sarcoma Service at Memorial Sloan Kettering retweeted
As a recipient of numerous ASCO Conquer Cancer grants, I can attest to the power and value of these opportunities. connection.asco.org/magazine…. @MSKSarcoma @MSK_DeptOfMed @ASCO @ConquerCancerFd
Nirogacestat, a New Desmoid Tumor Treatment, Improves Outcomes for People With Sarcoma mskcc.org/news/nirogacestat-… @AimeeCragoMD Dr. Sam Singer, MSK, Dr. Joe Erinjeri, Dr. Robert Lefkowitz @DTRFoundation @AmericanCancer @SpringWorksTx @RareDiseases @debschrag
ALT DeFi study - Global phase 3, randomized study of 142 pts with desmoid tumor. Nirogacestat significantly improves progression free survival (HR 0.29 p<0.0001), overall response rates (41 vs 8%) and improves desmoid related pain, physical function and mobility. Study validates the first desmoid-specific, patient reported outcome PRO instrument developed at MSK in collaboration with patient advocacy group DTRF.
Congratulations to all desmoid pts/families, pt advocacy @DTRFoundation, Mrinal Gounder @MSKCancerCenter desmoid team, co-investigators globally, @SpringWorksTx. A great model for drug development in @RareDiseases - pt advocacy working together w academia, industry & regulators.
Sarcoma Service at Memorial Sloan Kettering retweeted
Mrs. @MichelleObama has received nearly 2,000 letters every month — which are part of the inspiration behind her new book “The Light We Carry.”
Take a look at the story of one woman who wrote a letter in 2020 and found comfort in Mrs. Obama’s words during a difficult time.
Sarcoma Service at Memorial Sloan Kettering retweeted
MSK fellow extraordinaire, Dr. Lauren Banks provides insightful perspective into the status of immunotherapy for sarcoma. Privileged to co-mentor with Dr. Klebanoff with whom she's conducting ground breaking research @KlebanoffLab @WTapMD @MSK_DeptOfMed
The Role of #Immunotherapy in the Management of #SoftTissueSarcomas: Current Landscape and Future Outlook: buff.ly/3zjyRPs Published by Dr. Lauren B. Banks and @sandrapdangelo of @MSKCancerCenter @MSKSarcoma
#scmsm #sarcoma #ImmunoOnc
Sarcoma Service at Memorial Sloan Kettering retweeted
Share your story.
liferaftgroup.org/2022/02/it…
Sarcoma Service at Memorial Sloan Kettering retweeted
Rare, often misdiagnosed, accounts for 1% of all adult cancers and 15 to 20% of childhood cancers. In 2022, an estimated 17,000 people will be diagnosed, and over 7,200 people will die, 42% of diagnosed cases.
Read more here: healthykcmag.com/fighting-ca…
#sarcomaawarenessmonth
Sarcoma Service at Memorial Sloan Kettering retweeted
It's officially #SarcomaAwarenessMonth. Will you retweet to raise sarcoma awareness?
Sarcoma Service at Memorial Sloan Kettering retweeted
Excited to announce @DrVickersUAB of @uabnews has been selected to serve as MSK President and CEO beginning this September. He is an internationally recognized pancreatic cancer surgeon and researcher and an academic medical leader. bit.ly/3A54yxR
Sarcoma Service at Memorial Sloan Kettering retweeted
Nivolumab with bempegaldesleukin in sarcoma now published in @NatureComms. A collaborative effort with my colleagues @MSKSarcoma, @WTapMD, MSK computational biologists (Allison Richards, Mark Donoghue) and MDA colleagues @APConley77) nature.com/articles/s41467-0… @MSKCancerCenter 1/8
Sarcoma Service at Memorial Sloan Kettering retweeted
Our latest work is out in @NatureComms. With @fsanchezvega, @WTapMD, Samuel Singer, and colleagues at @MSKSarcoma
@MSKCancerCenter, we present a genomic analysis of 2,138 tumors representing 45 subtypes of soft tissue and bone #sarcoma (1/x). 🧵
disq.us/t/48gjq1m
Sarcoma Service at Memorial Sloan Kettering retweeted
We're looking for a new postdoc to help with our NIH project on #desmoid tumors. Email or DM if you know someone who might be interested! nature.com/naturecareers/job…